US Patent 6,432,452: What Is Claimed and How Broad Is the Scope?
US Patent 6,432,452 claims a topical treatment method for skin cancer using angeloyl-substituted ingenanes derived from Euphorbia peplus sap, including active derivatives with “the same activity” as the parent ingenane.
What exactly does claim 1 cover?
Claim 1 defines the core invention as a method of treatment with a specific class of actives delivered topically.
Claim 1 (independent) elements
- Method type: “A method of treating a subject with skin cancer”
- Route: “topically administering” to the subject
- Dosage standard: “a therapeutically effective amount”
- Active ingredient scope:
- “at least one compound selected from the group consisting of”
- (A) “an angeloyl-substituted ingenane obtained from the sap of Euphorbia peplus”
- (B) “an active derivative of an angeloyl-substituted ingenane obtained from the sap of Euphorbia peplus”
- Activity requirement for derivatives: derivative “exhibits the same activity as” the referenced angeloyl-substituted ingenane
Claim 1 functional scope in plain business terms
- The patent does not only cover a single molecule; it covers a family defined by:
- origin (must be “obtained from the sap of Euphorbia peplus”), and
- chemical class (angeloyl-substituted ingenanes), and
- equivalence for derivatives (same activity as the parent compound).
How broad is the chemical scope (and what is a limiting feature)?
The chemical scope is broad in that it includes:
- parent angeloyl-substituted ingenanes from the plant sap; and
- “active derivatives” that keep the same activity.
The key limiting features are:
- derivation/source constraint: the parent angeloyl-substituted ingenane must be “obtained from the sap,” and the derivative is defined as “an active derivative of” that sap-obtained parent;
- activity equivalence: the derivative must “exhibit the same activity.”
Practical implication for freedom-to-operate
- A competitor using a compound that is structurally in the same general “ingenane with angeloyl” class may still be challenged if the compound is argued to be an “active derivative” of sap-derived parent.
- A product with a different scaffolding or a different plant source can avoid the claim’s origin and class framing, unless it is characterized as an “active derivative” of the sap-derived angeloyl-substituted ingenanes with the same activity.
How specific do the dependent claims become?
Claims 2-12 layer specificity on top of claim 1 along two axes: which derivative and which cancer indication, plus how extracted.
Dependent claims and their added constraints
| Claim |
What it narrows or defines |
Effect on scope |
| 2 |
Derivative is “an acetylated derivative.” |
Limits derivatives to acetylation type. |
| 3 |
Compounds are “20-O-acetyl-ingenol-3-angelate” and “an ester derivative of a 20-O-acetyl-ingenol-3-angelate.” |
Converts the class into explicit named compound + ester derivatives. |
| 4 |
Includes “pharmaceutically acceptable salt” of 20-O-acetyl-ingenol-3-angelate or its ester derivative. |
Adds formulation/solid form variants without changing active identity. |
| 5 |
One preparation pathway: “obtained… by… aqueous extraction and collecting the aqueous fraction.” |
Process-limited in dependent claim, helpful for distinguishing but also adds another claim hook. |
| 6 |
Another pathway: extract sap with “95% v/v ethanol,” discard soluble fraction, retain solid fraction. |
Another process-limited variant. |
| 7-11 |
Skin cancer types: “malignant melanoma,” “Merkel cell carcinoma,” “squamous cell carcinoma,” “basal cell carcinoma,” “solar keratosis.” |
Indication specificity. |
| 12 |
Subject is “human.” |
Adds demographic clarity; usually easy to satisfy but narrows claim language. |
Does the patent cover all skin cancers or only enumerated ones?
Claim 1 covers skin cancer broadly. Dependent claims 7-11 then specify particular cancer types:
- malignant melanoma
- Merkel cell carcinoma
- squamous cell carcinoma
- basal cell carcinoma
- solar keratosis
Because claim 1 is not limited to one cancer type, the dependent claims do not restrict claim 1. They create narrower embodiments for enforceability and claim differentiation.
What products and actives are directly implicated by the claim set?
Actives expressly named
The claims explicitly name these compounds within dependent claim 3:
- 20-O-acetyl-ingenol-3-angelate
- ester derivative of 20-O-acetyl-ingenol-3-angelate
Derivative type category
- “active derivative” in claim 1
- “acetylated derivative” in claim 2
Ingredient identity vs formulation identity
Claim 4 covers:
- pharmaceutically acceptable salts of the named active
- ester derivative salts where applicable
Claim 1 itself does not require a particular carrier, vehicle, or concentration. It requires:
- topical administration
- therapeutically effective amount
What does the extraction/process language do in the landscape?
Dependent claims 5 and 6 recite particular extraction schemes, which matters in two ways:
-
Independent infringement routes
These claims are dependent, so they attach to claim 1’s topical treatment method using the defined compound. A party who uses the same active but a different extraction process may avoid claims 5 and 6 specifically while still potentially falling under claim 1 and claims 2-4 and 7-12.
-
Patent prosecution and validity positioning
Process limitations often exist to distinguish prior art during prosecution. Even if a competitor uses a different manufacturing process, the existence of these dependent claims can shape how prior art is parsed and how claim scope is defended.
Where is claim 1 likely strongest in litigation terms?
Claim 1’s enforcement strength typically comes from the combination of:
- route (topical)
- treatment purpose (skin cancer)
- active class (angeloyl-substituted ingenanes from Euphorbia peplus sap)
- derivative coverage by activity equivalence (“same activity”)
This combination can be difficult to design around if a competitor’s product is:
- topical,
- intended for skin cancer,
- based on angeloyl-substituted ingenane derivatives associated with Euphorbia peplus sap,
- and supported with activity claims that could be characterized as “the same activity.”
How does this patent likely relate to the modern market for ingenol derivatives?
The patent language uses “20-O-acetyl-ingenol-3-angelate” and ester derivatives. That naming aligns with the known active class historically associated with Euphorbia-derived ingenol esters used in dermatology. The claims also cover multiple skin cancer indications beyond actinic (solar) keratosis, including:
- basal cell carcinoma
- squamous cell carcinoma
- melanoma and Merkel cell carcinoma
From an investment or R&D portfolio view, the claim set creates a broad “label-adjacent” coverage concept: if a topical ingenol-ester-like product is positioned for multiple non-melanoma and keratinocyte-related indications, the independent claim 1’s skin cancer coverage is a central risk.
Patent landscape implications: what claim features create clustering risk?
Key claim features that can anchor a landscape “hot zone”
- Chemical class anchored to plant sap origin
- “obtained from the sap of Euphorbia peplus”
- Angeloyl-substituted ingenane core
- class-level rather than single molecule only
- Derivative definition by activity equivalence
- “exhibits the same activity”
- Topical treatment method
- route-limited but common in dermatology
- Cancer indication breadth
- claim 1 broad skin cancer; dependents list serious malignancies
How competitors might respond (design-around patterns)
Even without asserting specifics, the claim architecture incentivizes the common strategies:
- change route (not topical) or avoid “method of treating” therapeutic claims;
- choose a non-angeloyl-substituted ingenane core;
- avoid dependence on Euphorbia peplus sap-derived actives, at least as claimed;
- create derivatives with altered activity profiles that can be argued not to meet “same activity.”
The “same activity” phrase is a litigation focal point because it turns chemistry into a functional comparison requiring evidentiary support.
Scope map: which parts are “worth engineering around”?
Highest-risk claim hooks
- Claim 1 class coverage: any “angeloyl-substituted ingenane” from Euphorbia peplus sap plus “active derivatives” with “same activity”
- Topical delivery + therapeutic intent
- Derivative defined by activity equivalence
Secondary claim hooks
- Acetylated derivative (claim 2)
- Named actives and ester derivatives (claim 3)
- Salt forms (claim 4)
- Extraction process (claims 5-6)
- Specific malignancies and solar keratosis (claims 7-11)
- Human subject (claim 12)
What would a complete landscape read typically include for this patent?
For an enforceability and competitive positioning scan around US 6,432,452, a buyer or R&D team would map:
- continuation family members (if any),
- related patents covering:
- specific ester derivatives (like 20-O-acetyl-ingenol-3-angelate),
- formulations and dosing regimens,
- manufacturing and extraction,
- therapeutic uses in specific cancers,
- and any “active derivative” claim expansions.
Because this request is limited to the claim set you provided, this analysis focuses on claim-driven landscape logic rather than enumerating unrelated patents.
Key Takeaways
- US 6,432,452 claims topical treatment of skin cancer using angeloyl-substituted ingenanes from Euphorbia peplus sap, including active derivatives that show the same activity as the sap-derived parent.
- Claim 1 is the dominant scope anchor: it covers a class and derivative concept, not only a single molecule.
- Dependent claims narrow to:
- acetylated derivatives (claim 2),
- explicit 20-O-acetyl-ingenol-3-angelate and ester derivatives (claim 3),
- salts (claim 4),
- two extraction/process approaches (claims 5-6),
- and multiple malignancies plus solar keratosis (claims 7-11).
- The most landscape-relevant enforcement hooks are: topical route, skin cancer treatment, Euphorbia peplus sap origin, angeloyl-substituted ingenane class, and activity equivalence for derivatives.
FAQs
1) Does claim 1 require a specific named drug?
No. Claim 1 covers angeloyl-substituted ingenanes from Euphorbia peplus sap and “active derivatives” with the same activity. Named compounds appear in dependent claim 3.
2) What is the main limit on “active derivatives” in claim 1?
The derivative must “exhibit the same activity” as the sap-derived angeloyl-substituted ingenane.
3) Are manufacturing steps part of the strongest claim?
No. Claims 5 and 6 add extraction process limitations, but those are dependent on claim 1. The broad enforceability anchor is claim 1’s treatment method and compound class.
4) Does the patent cover melanoma and Merkel cell carcinoma?
Yes. Claims 7 and 8 specify those skin cancer types as embodiments of claim 1.
5) Can salt forms be within scope without changing the drug molecule?
Yes. Claim 4 includes pharmaceutically acceptable salts of 20-O-acetyl-ingenol-3-angelate or its ester derivative.
References (APA)
[1] US Patent 6,432,452. (n.d.). Method for treating skin cancer using Euphorbia peplus derived angeloyl-substituted ingenanes and derivatives (claims as provided).
